148 related articles for article (PubMed ID: 18832778)
1. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3.
Ishino M; Takeishi Y; Niizeki T; Watanabe T; Nitobe J; Miyamoto T; Miyashita T; Kitahara T; Suzuki S; Sasaki T; Bilim O; Kubota I
Circ J; 2008 Nov; 72(11):1800-5. PubMed ID: 18832778
[TBL] [Abstract][Full Text] [Related]
2. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
3. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure.
Niizeki T; Takeishi Y; Arimoto T; Takahashi T; Okuyama H; Takabatake N; Nozaki N; Hirono O; Tsunoda Y; Shishido T; Takahashi H; Koyama Y; Fukao A; Kubota I
Circ J; 2005 Aug; 69(8):922-7. PubMed ID: 16041160
[TBL] [Abstract][Full Text] [Related]
4. Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure.
Liu H; Guo X; Yao K; Wang C; Chen G; Gao W; Yuan J; Yu W; Ge J
Biomed Res Int; 2015; 2015():817615. PubMed ID: 26579541
[TBL] [Abstract][Full Text] [Related]
5. Heart-type fatty acid-binding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients.
Niizeki T; Takeishi Y; Arimoto T; Takabatake N; Nozaki N; Hirono O; Watanabe T; Nitobe J; Harada M; Suzuki S; Koyama Y; Kitahara T; Sasaki T; Kubota I
J Card Fail; 2007 Mar; 13(2):120-7. PubMed ID: 17395052
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of Pentraxin 3 in diagnosing the severity and cardiovascular function of the children with sepsis].
Kang X; Zhu Y; Zhang X
Zhonghua Er Ke Za Zhi; 2015 Aug; 53(8):592-8. PubMed ID: 26717657
[TBL] [Abstract][Full Text] [Related]
7. Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction.
Matsui S; Ishii J; Kitagawa F; Kuno A; Hattori K; Ishikawa M; Okumura M; Kan S; Nakano T; Naruse H; Tanaka I; Nomura M; Hishida H; Ozaki Y
Atherosclerosis; 2010 May; 210(1):220-5. PubMed ID: 19945702
[TBL] [Abstract][Full Text] [Related]
8. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.
Suzuki S; Takeishi Y; Niizeki T; Koyama Y; Kitahara T; Sasaki T; Sagara M; Kubota I
Am Heart J; 2008 Jan; 155(1):75-81. PubMed ID: 18082493
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of Serum Levels of Heart-Type Fatty Acid Binding Protein and High Sensitivity C-Reactive Protein in Patients With Increased Levels of Amino-Terminal Pro-B Type Natriuretic Peptide.
Jeong JH; Seo YH; Ahn JY; Kim KH; Seo JY; Kim MJ; Lee HT; Park PW
Ann Lab Med; 2016 Sep; 36(5):420-6. PubMed ID: 27374706
[TBL] [Abstract][Full Text] [Related]
10. Multimarker approach to risk stratification among patients with advanced chronic heart failure.
Yin WH; Chen JW; Feng AN; Lin SJ; Young S
Clin Cardiol; 2007 Aug; 30(8):397-402. PubMed ID: 17680620
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
O'Donoghue M; de Lemos JA; Morrow DA; Murphy SA; Buros JL; Cannon CP; Sabatine MS
Circulation; 2006 Aug; 114(6):550-7. PubMed ID: 16880323
[TBL] [Abstract][Full Text] [Related]
12. Cardiac sympathetic denervation and ongoing myocardial damage for prognosis in early stages of heart failure.
Arimoto T; Takeishi Y; Niizeki T; Nozaki N; Hirono O; Watanabe T; Nitobe J; Tsunoda Y; Suzuki S; Koyama Y; Kitahara T; Okada A; Takahashi K; Kubota I
J Card Fail; 2007 Feb; 13(1):34-41. PubMed ID: 17339001
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure.
Ishii J; Cui W; Kitagawa F; Kuno T; Nakamura Y; Naruse H; Mori Y; Ishikawa T; Nagamura Y; Kondo T; Oshima H; Nomura M; Ezaki K; Hishida H
Clin Chem; 2003 Dec; 49(12):2020-6. PubMed ID: 14633873
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of the heart-type fatty acid-binding protein and the Pulmonary Embolism Severity Index in patients with acute pulmonary embolism in the emergency department.
Lauque D; Maupas-Schwalm F; Bounes V; Juchet H; Bongard V; Roshdy A; Botella JM; Charpentier S
Acad Emerg Med; 2014 Oct; 21(10):1143-50. PubMed ID: 25308138
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of pentraxin 3 in patients with chronic heart failure.
Kotooka N; Inoue T; Aoki S; Anan M; Komoda H; Node K
Int J Cardiol; 2008 Oct; 130(1):19-22. PubMed ID: 18045709
[TBL] [Abstract][Full Text] [Related]
16. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome.
Mjelva ØR; Pönitz V; Brügger-Andersen T; Grundt H; Staines H; Nilsen DW
Eur J Prev Cardiol; 2016 Jul; 23(11):1130-40. PubMed ID: 26635361
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure.
Ishii J; Nomura M; Nakamura Y; Naruse H; Mori Y; Ishikawa T; Ando T; Kurokawa H; Kondo T; Nagamura Y; Ezaki K; Hishida H
Am J Cardiol; 2002 Mar; 89(6):691-5. PubMed ID: 11897211
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction.
Latini R; Maggioni AP; Peri G; Gonzini L; Lucci D; Mocarelli P; Vago L; Pasqualini F; Signorini S; Soldateschi D; Tarli L; Schweiger C; Fresco C; Cecere R; Tognoni G; Mantovani A;
Circulation; 2004 Oct; 110(16):2349-54. PubMed ID: 15477419
[TBL] [Abstract][Full Text] [Related]
19. [Heart fatty acid binding protein in patients hospitalized because of worsening heart failure. Relation to prognosis of death].
Mazovets OL; Trifonov IR; Katrukha AG; Bereznikova AV; Medvedeva MV; Deev AD; Gratsianksiĭ NA
Kardiologiia; 2008; 48(1):24-9. PubMed ID: 18260992
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of both cardiomyocyte membrane and myofibril damage markers predict adverse outcomes in patients with chronic heart failure.
Setsuta K; Seino Y; Kitahara Y; Arau M; Ohbayashi T; Takano T; Mizuno K
Circ J; 2008 Apr; 72(4):569-74. PubMed ID: 18362427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
